StockNews.AI
CUE
StockNews.AI
127 days

Cue Biopharma to Host Business Update Call and Webcast

1. Cue Biopharma will hold a business update conference call on April 15, 2025. 2. The company is developing biologics targeting T cells for cancer and autoimmune diseases. 3. Live and archived webcasts will be available on the company’s website.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming business updates and advancements in therapeutics typically boost investor confidence, as seen with companies like Moderna during their significant announcements.

How important is it?

The company's innovative approach and scheduled updates can influence investor sentiment positively.

Why Short Term?

Immediate market attention usually follows business updates, which can affect stock prices quickly.

Related Companies

MRNAREGNBMRN
April 14, 2025 17:02 ET  | Source: Cue Biopharma, Inc. BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET The live and archived webcast will also be available in the Investors and Media section of the Company’s website. The webcast will be archived for 30 days. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics. For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn. Investor Contact Marie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Inc.mcampinell@cuebio.com Media ContactJonathan PappasLifeSci Communicationsjpappas@lifescicomms.com

Related News